- Full text PDF available (2)
- This year (1)
- Last 5 years (3)
- Last 10 years (3)
Journals and Conferences
Preclinical mouse models suggest that the gut microbiome modulates tumor response to checkpoint blockade immunotherapy; however, this has not been well-characterized in human cancer patients. Here we… (More)
BACKGROUND Immune related adverse events (irAEs) are common side effects of checkpoint inhibitory (CPI) therapies targeting CTLA-4 and PD-1/PD-L1. Grover's disease is an uncommon dermatologic… (More)
[This corrects the article DOI: 10.1186/s40425-016-0157-6.].